Lund, Sweden, June 14, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Johan Giléus as the company’s new Chief Financial Officer as of August 12, 2024. Mr. Giléus has extensive expertise as a financial executive with more than 25 years of experience leading financial strategy and operations across a number of companies and industries, including overseeing a large Phase 3 clinical trial and outlicensing in Japan. Most recently, he served as Chief Financial Officer and Deputy Chief Executive Officer at InDex Pharmaceuticals, which was recently subject to a successful reverse merger with Flerie Invest.
Mr. Giléus will succeed Marie Svensson, who has served as Alligator’s Chief Financial Officer since 2020. Marie Svensson will remain in the Company.
“It is with great pleasure that we welcome Johan to the Alligator team and we are looking forward to benefiting from his experience and leadership as we continue to develop Alligator as well as develop the clinical and commercial potential of our robust immuno-oncology pipeline,” said Søren Bregenholt, CEO of Alligator Bioscience. “On behalf of myself, the Board and the whole Alligator team I would like to thank Marie for her hard work and dedication as our CFO for the last 4 years, and I am very happy that Marie remains at Alligator in a new role. We remain well positioned to achieve our current strategic objectives, including a commercial partnership for our lead candidate mitazalimab ahead of its Phase 3 evaluation, as well as the continued development of our preclinical and early-stage assets.”
“Alligator is making fantastic progress in its mission to develop innovative treatments for patients with hard-to-treat cancers,” said Johan Giléus, CFO of Alligator Bioscience. “I am very pleased to be joining Alligator’s experienced and highly-regarded team to help continue the financial development and growth of the company at this exciting and important time.”
About Johan Giléus
Johan Giléus joins Alligator Bioscience from InDex Pharmaceuticals where he served as Chief Financial Officer from 2017, overseeing share and rights issues which raised more than SEK 700 million (c. $70 million). He stepped up as interim CEO in 2022, during which time the company ramped up a Phase 3 clinical trial in more than 200 sites in 30 countries. He was subsequently appointed Deputy Chief Executive Officer in 2023 and later the same year he led the work to sign an outlicensing agreement in Japan. Until May 2015, he was a partner at Deloitte AB with a focus on M&A, external financial reporting and other stock market issues for Swedish and international clients. Mr Giléus has also served on the boards of Haldex AB and BHG Group AB, including chairing their respective audit committees. Mr. Giléus studied business and finance at Stockholm University.